Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3C101-DM1
- Development stage
- Preclinical
- Lead developer
- Tottori University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
**3C101-DM1** is an experimental, fully human epithelial cell adhesion molecule-targeted antibody-drug conjugate generated from the anti-EpCAM monoclonal-antibody clone 3C101 and the maytansinoid cytotoxic payload DM1. The conjugate was produced using affinity peptide-based chemical conjugation, a site-specific IgG-labeling method. In a published in-vitro evaluation, 3C101-DM1 showed cytotoxicity against HCT116 human colorectal cancer cells, with a reported half-maximal inhibitory concentration of 0.553 micrograms per milliliter after 60 hours. It is a preclinical research-stage ADC candidate rather than a clinically developed or marketed medicine.
- Other names
- CCAP-DM1-3C101CCAP-DM-1-3C101CCAP-DM 1-3C101
02
Targets
TUBB (Tubulin (alpha and beta subunits))EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on 3C101-DM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3C101-DM1.